应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02592 拨康视云-B
圣诞节休市 12-24 12:08:24
5.450
-0.200
-3.54%
最高
5.790
最低
5.100
成交量
72.65万
今开
5.790
昨收
5.650
日振幅
12.21%
总市值
46.05亿
流通市值
46.05亿
总股本
8.45亿
成交额
383.48万
换手率
0.09%
流通股本
8.45亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
拨康视云-B盘中异动 股价大跌5.13%
市场透视 · 12-23 15:35
拨康视云-B盘中异动 股价大跌5.13%
每日卖空追踪 | 拨康视云-B 12月22日卖空量成交1.8万股,卖空比例为0.94%
市场透视 · 12-22
每日卖空追踪 | 拨康视云-B 12月22日卖空量成交1.8万股,卖空比例为0.94%
每日卖空追踪 | 拨康视云-B 12月17日卖空量成交1.9万股,卖空比例为0.99%
市场透视 · 12-17
每日卖空追踪 | 拨康视云-B 12月17日卖空量成交1.9万股,卖空比例为0.99%
拨康视云-B12月16日主力净流出61.5万元 散户资金买入
市场透视 · 12-16
拨康视云-B12月16日主力净流出61.5万元 散户资金买入
港股异动 | 拨康视云-B(02592)一度跌近15% CBT-199眼科候选药物在美递交新药临床试验申请
智通财经 · 12-16
港股异动 | 拨康视云-B(02592)一度跌近15% CBT-199眼科候选药物在美递交新药临床试验申请
拨康视云-B(02592)向美国药管局提交有关CBT-199的新药临床试验申请
智通财经 · 12-15
拨康视云-B(02592)向美国药管局提交有关CBT-199的新药临床试验申请
每日卖空追踪 | 拨康视云-B 12月15日卖空量成交5.7万股,卖空比例为1.33%
市场透视 · 12-15
每日卖空追踪 | 拨康视云-B 12月15日卖空量成交5.7万股,卖空比例为1.33%
拨康视云-B(02592)成功举行CBT-004的第2期临床试验后会议
智通财经 · 12-12
拨康视云-B(02592)成功举行CBT-004的第2期临床试验后会议
每日卖空追踪 | 拨康视云-B 12月12日卖空量成交1.15万股,卖空比例为0.7%
市场透视 · 12-12
每日卖空追踪 | 拨康视云-B 12月12日卖空量成交1.15万股,卖空比例为0.7%
拨康视云-B12月12日主力净流出100.4万元 散户资金买入
市场透视 · 12-12
拨康视云-B12月12日主力净流出100.4万元 散户资金买入
每日卖空追踪 | 拨康视云-B 12月10日卖空量成交3.45万股,卖空比例为1.69%
市场透视 · 12-10
每日卖空追踪 | 拨康视云-B 12月10日卖空量成交3.45万股,卖空比例为1.69%
港股异动 | 拨康视云-B(02592)现涨超4% 附属将与美国FDA讨论CBT-004研发事项
智通财经 · 12-10
港股异动 | 拨康视云-B(02592)现涨超4% 附属将与美国FDA讨论CBT-004研发事项
每日卖空追踪 | 拨康视云-B 12月09日卖空量成交2.1万股,卖空比例为0.98%
市场透视 · 12-09
每日卖空追踪 | 拨康视云-B 12月09日卖空量成交2.1万股,卖空比例为0.98%
拨康视云-B12月09日主力净流出1.5万元 散户资金买入
市场透视 · 12-09
拨康视云-B12月09日主力净流出1.5万元 散户资金买入
每日卖空追踪 | 拨康视云-B 12月08日卖空量成交1.6万股,卖空比例为0.97%
市场透视 · 12-08
每日卖空追踪 | 拨康视云-B 12月08日卖空量成交1.6万股,卖空比例为0.97%
港股异动 | 拨康视云-B(02592)午后涨近8% 本周三附属将与美国FDA商讨CBT-004临床研发进程
智通财经 · 12-08
港股异动 | 拨康视云-B(02592)午后涨近8% 本周三附属将与美国FDA商讨CBT-004临床研发进程
每日卖空追踪 | 拨康视云-B 12月04日卖空量成交1.7万股,卖空比例为0.84%
市场透视 · 12-04
每日卖空追踪 | 拨康视云-B 12月04日卖空量成交1.7万股,卖空比例为0.84%
拨康视云-B12月04日获主力加仓79.7万元
市场透视 · 12-04
拨康视云-B12月04日获主力加仓79.7万元
港股异动 | 拨康视云-B(02592)盘中涨超4% 近一周累计涨幅逾八成 公司将加速CBT-009全球商业化潜力
智通财经 · 12-02
港股异动 | 拨康视云-B(02592)盘中涨超4% 近一周累计涨幅逾八成 公司将加速CBT-009全球商业化潜力
每日卖空追踪 | 拨康视云-B 12月01日卖空量成交4.85万股,卖空比例为1.75%
市场透视 · 12-01
每日卖空追踪 | 拨康视云-B 12月01日卖空量成交4.85万股,卖空比例为1.75%
加载更多
公司概况
公司名称:
拨康视云-B
所属市场:
SEHK
上市日期:
--
主营业务:
Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司,从事开发各种治疗方法。该公司专注于眼科疗法的内部发现、开发和商业化。该公司拥有两款核心产品 CBT-001和CBT-009,均为自主研发。该公司的核心产品CBT-001用于治疗翼状胬肉(一种良性增生性眼表疾病),已在美国和中国启动III期多区域临床试验(MRCT)。该公司的核心产品CBT-009用于治疗青少年近视(5至19岁儿童和青少年的近视),已完成I/II期临床试验。该公司的其他候选药物处于相对早期的开发阶段,包括另外两种临床阶段候选药物,即CBT-006和CBT-004,以及四种临床前阶段候选药物,即CBT-007、CBT-199、CBT-145和CBT-011。
发行价格:
--
{"stockData":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"拨康视云-B","latestPrice":5.45,"timestamp":1766549304008,"preClose":5.65,"halted":0,"volume":726500,"delay":0,"floatShares":844999999,"shares":844999999,"eps":-1.6215512146567546,"marketStatus":"圣诞节休市","change":-0.2,"latestTime":"12-24 12:08:24","open":5.79,"high":5.79,"low":5.1,"amount":3834780,"amplitude":0.122124,"askPrice":5.48,"askSize":5500,"bidPrice":5.45,"bidSize":8500,"shortable":3,"etf":0,"ttmEps":-1.3098074590189432,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":7,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":5.65,"openAndCloseTimeList":[[1766539800000,1766548800000]],"volumeRatio":0.7244867829780256,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02592","defaultTab":"news","newsList":[{"id":"2593808411","title":"拨康视云-B盘中异动 股价大跌5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593808411","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593808411?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:35","pubTimestamp":1766475325,"startTime":"0","endTime":"0","summary":"2025年12月23日临近收盘15时35分,拨康视云-B股票出现异动,股价大幅跳水5.13%。截至发稿,该股报5.730港元/股,成交量186.8万股,换手率0.22%,振幅6.13%。拨康视云-B股票所在的生物技术行业中,整体跌幅为1.65%。其相关个股中,药明巨诺-B、东曜药业-B、昭衍新药涨幅较大,振幅较大的相关个股有翰思艾泰-B、华仁生物-B、药捷安康-B,振幅分别为38.38%、18.07%、17.78%。拨康视云-B公司简介:Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司,从事开发各种治疗方法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122315352597a096b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122315352597a096b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2593485707","title":"每日卖空追踪 | 拨康视云-B 12月22日卖空量成交1.8万股,卖空比例为0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485707?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:30","pubTimestamp":1766392232,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月22日,涨5.04%,卖空量成交1.8万股,较上一交易日减少40.98%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163606a46996fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222163606a46996fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2592099301","title":"每日卖空追踪 | 拨康视云-B 12月17日卖空量成交1.9万股,卖空比例为0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592099301","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592099301?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:30","pubTimestamp":1765960231,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月17日,涨8.02%,卖空量成交1.9万股,较上一交易日减少78.41%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163508a6ad261b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217163508a6ad261b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2592593496","title":"拨康视云-B12月16日主力净流出61.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2592593496","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592593496?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:15","pubTimestamp":1765872945,"startTime":"0","endTime":"0","summary":"12月16日, 拨康视云-B股价跌11.05%,报收4.99元,成交金额1352.0万元,换手率0.32%,振幅17.47%,量比1.06。拨康视云-B今日主力资金净流出61.5万元,上一交易日主力净流入283.2万元。该股近5个交易日下跌39.44%,主力资金累计净流入32.9万元;近20日主力资金累计净流入4469.3万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162005a6a8a541&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162005a6a8a541&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2591198671","title":"港股异动 | 拨康视云-B(02592)一度跌近15% CBT-199眼科候选药物在美递交新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2591198671","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591198671?lang=zh_cn&edition=full","pubTime":"2025-12-16 10:20","pubTimestamp":1765851607,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,拨康视云-B一度跌近15%,12月5日至今回撤逾四成。截至发稿,跌11.59%,报4.96港元,成交额677.98万港元。消息面上,拨康视发布公告称,12月15日,公司全资附属公司ADS Therapeutics LLC向美国食品及药物管理局提交有关CBT-199的新药临床试验申请。CBT-199已自2023年6月起于临床前动物研究中进行安全性和耐受性评估,有关研究预期将有助于未来的临床试验。另值得注意的是,1月3日,拨康视云两位基石投资者将迎来限售股解禁。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","BK4090","02592","BK1161"],"gpt_icon":0},{"id":"2591614559","title":"拨康视云-B(02592)向美国药管局提交有关CBT-199的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614559","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591614559?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:15","pubTimestamp":1765790138,"startTime":"0","endTime":"0","summary":"智通财经APP讯,拨康视云-B 发布公告,于2025年12月15日,本公司全资附属公司ADS Therapeutics LLC向美国食品及药物管理局提交有关CBT-199的新药临床试验申请。诚如本公司日期为2025年6月24日的招股章程所披露,本集团已于2023年在中国开始 CBT-199的药物发现过程。CBT-199已自2023年6月起于临床前动物研究中进行安全性和耐受性评估,有关研究预期将有助于未来的临床试验。提交新药临床试验申请为美国药管局启动药物审查程序以及取得监管批准以展开CBT-199的临床试验的第一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","BK4090","02592","BK1161"],"gpt_icon":0},{"id":"2591100641","title":"每日卖空追踪 | 拨康视云-B 12月15日卖空量成交5.7万股,卖空比例为1.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591100641","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591100641?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787431,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月15日,跌19.51%,卖空量成交5.7万股,较上一交易日增加46.15%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163501a44d41af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163501a44d41af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2590571809","title":"拨康视云-B(02592)成功举行CBT-004的第2期临床试验后会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2590571809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590571809?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:36","pubTimestamp":1765528591,"startTime":"0","endTime":"0","summary":"第2期临床试验后会议乃基于2025年5月完成的第2期临床试验结果及2025年7月完成的临床试验报告而举行,该报告显示CBT-004在受试者中具有安全性且耐受性良好,并达到主要疗效终点及若干次要疗效终点。公司认为,成功举行第2期临床试验后会议标志着CBT-004临床开发取得重大进展,尤其是推动其进入第3期临床研究,为CBT-004新药申请及获批后的商业化铺平道路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4090","02592","CBT","BK1161"],"gpt_icon":0},{"id":"2591897996","title":"每日卖空追踪 | 拨康视云-B 12月12日卖空量成交1.15万股,卖空比例为0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591897996","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591897996?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528229,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月12日,跌1.13%,卖空量成交1.15万股,较上一交易日减少79.46%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216531995398cac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216531995398cac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2591689760","title":"拨康视云-B12月12日主力净流出100.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2591689760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591689760?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:15","pubTimestamp":1765527317,"startTime":"0","endTime":"0","summary":"12月12日, 拨康视云-B股价跌1.13%,报收6.97元,成交金额1101.8万元,换手率0.20%,振幅14.47%,量比0.58。拨康视云-B今日主力资金净流出100.4万元,上一交易日主力净流入16.3万元。该股近5个交易日下跌12.63%,主力资金累计净流出190.2万元;近20日主力资金累计净流入4269.1万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212161713a69b6fae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212161713a69b6fae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2590302463","title":"每日卖空追踪 | 拨康视云-B 12月10日卖空量成交3.45万股,卖空比例为1.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590302463","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590302463?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:30","pubTimestamp":1765355432,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月10日,跌2.43%,卖空量成交3.45万股,较上一交易日减少40%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163646a72f4fc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163646a72f4fc5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2590377514","title":"港股异动 | 拨康视云-B(02592)现涨超4% 附属将与美国FDA讨论CBT-004研发事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2590377514","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590377514?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:55","pubTimestamp":1765338945,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,拨康视云-B(02592)现涨超4%,截至发稿,涨4.13%,报8.58港元,成交额1182.43万港元。消息面上,拨康视云此前公告,本公司于美国加利福尼亚州注册成立的全资附属公司Cloudbreak USA排定于2025年12月10日与美国食品及药物管理局正式举行第2期临床试验后会议,该会议涉及集团临床阶段候选药物 CBT-004。此次第2期临床试验后会议是CBT-004研发进程中一个重要的里程碑,用于讨论CBT-004研发进程中潜在的第三阶段临床试验开发以及新药申请的相关要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592","BK4090","BK1161","CBT"],"gpt_icon":0},{"id":"2590232160","title":"每日卖空追踪 | 拨康视云-B 12月09日卖空量成交2.1万股,卖空比例为0.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590232160","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590232160?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269031,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月09日,跌5.61%,卖空量成交2.1万股,较上一交易日减少57.14%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163502979826a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163502979826a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2590732167","title":"拨康视云-B12月09日主力净流出1.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2590732167","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590732167?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:16","pubTimestamp":1765268160,"startTime":"0","endTime":"0","summary":"12月09日, 拨康视云-B股价跌5.61%,报收8.24元,成交金额1818.1万元,换手率0.26%,振幅12.83%,量比0.78。拨康视云-B今日主力资金净流出1.5万元,上一交易日主力净流出0万元。该股近5个交易日下跌5.83%,主力资金累计净流入168.4万元;近20日主力资金累计净流入4457.8万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120916224797981f72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120916224797981f72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2590365783","title":"每日卖空追踪 | 拨康视云-B 12月08日卖空量成交1.6万股,卖空比例为0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365783","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590365783?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:30","pubTimestamp":1765182630,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月08日,涨9.13%,卖空量成交1.6万股,较上一交易日减少90.7%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163451953109c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163451953109c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2589338182","title":"港股异动 | 拨康视云-B(02592)午后涨近8% 本周三附属将与美国FDA商讨CBT-004临床研发进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2589338182","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589338182?lang=zh_cn&edition=full","pubTime":"2025-12-08 13:46","pubTimestamp":1765172812,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,拨康视云-B午后涨近8%,截至发稿,涨7.5%,报8.6港元,成交额765.31万港元。本集团于2023年12月开始CBT-004的第2期临床试验,并于2025年5月完成。本集团已于2025年7月完成临床试验报告并计划与美国食品及药物管理局举行第2期临床试验后会议。此次第2期临床试验后会议是CBT-004研发进程中一个重要的里程碑,用于讨论CBT-004研发进程中潜在的第三阶段临床试验开发以及新药申请的相关要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","02592","BK4090","BK1161"],"gpt_icon":0},{"id":"2588385998","title":"每日卖空追踪 | 拨康视云-B 12月04日卖空量成交1.7万股,卖空比例为0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588385998","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588385998?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837032,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月04日,涨6.97%,卖空量成交1.7万股,较上一交易日减少63.83%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163506952a7c13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163506952a7c13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2588838597","title":"拨康视云-B12月04日获主力加仓79.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588838597","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588838597?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:15","pubTimestamp":1764836145,"startTime":"0","endTime":"0","summary":"12月04日, 拨康视云-B股价涨6.97%,报收9.51元,成交金额1840.1万元,换手率0.24%,振幅8.89%,量比0.47。拨康视云-B今日主力资金净流入79.7万元,上一交易日主力净流入149.3万元。该股近5个交易日上涨30.17%,主力资金累计净流入1933.4万元;近20日主力资金累计净流入4574.2万元,其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204161946952a7335&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204161946952a7335&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2588088954","title":"港股异动 | 拨康视云-B(02592)盘中涨超4% 近一周累计涨幅逾八成 公司将加速CBT-009全球商业化潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088954","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588088954?lang=zh_cn&edition=full","pubTime":"2025-12-02 10:20","pubTimestamp":1764642042,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,拨康视云-B盘中涨超4%,近一周交易日累计涨幅逾八成。消息面上,近日,拨康视云-B发布公告,公司于美国特拉华州注册成立的全资附属公司ADS Therapeutics LLC已成功在日本及欧洲成功申请专利,该等专利涉及集团核心产品之一CBT-009。公司认为,该等专利申请的成功是CBT-009研发进程中的重要里程碑,将提升CBT-009的全球覆盖范围,并促进商业化进程。有关合作及许可安排预期将提升并加速CBT-009的全球商业化潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","BK1161","BK4090","02592"],"gpt_icon":0},{"id":"2588725450","title":"每日卖空追踪 | 拨康视云-B 12月01日卖空量成交4.85万股,卖空比例为1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725450","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588725450?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:30","pubTimestamp":1764577831,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月01日,涨2.54%,卖空量成交4.85万股,较上一交易日减少37.42%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163440a4c55194&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163440a4c55194&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0}],"profile":{"websiteUrl":"http://cloudbreakpharma.com","stockEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0481},{"period":"3month","weight":0.1522},{"period":"6month","weight":-0.4604},{"period":"ytd","weight":-0.4604}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0251},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2846},{"period":"ytd","weight":0.2871}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Cloudbreak Pharma Inc是一家临床阶段的眼科生物技术公司,从事开发各种治疗方法。该公司专注于眼科疗法的内部发现、开发和商业化。该公司拥有两款核心产品 CBT-001和CBT-009,均为自主研发。该公司的核心产品CBT-001用于治疗翼状胬肉(一种良性增生性眼表疾病),已在美国和中国启动III期多区域临床试验(MRCT)。该公司的核心产品CBT-009用于治疗青少年近视(5至19岁儿童和青少年的近视),已完成I/II期临床试验。该公司的其他候选药物处于相对早期的开发阶段,包括另外两种临床阶段候选药物,即CBT-006和CBT-004,以及四种临床前阶段候选药物,即CBT-007、CBT-199、CBT-145和CBT-011。","exchange":"SEHK","name":"拨康视云-B","nameEN":"CLOUDBREAK-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拨康视云-B,02592,拨康视云-B股票,拨康视云-B股票老虎,拨康视云-B股票老虎国际,拨康视云-B行情,拨康视云-B股票行情,拨康视云-B股价,拨康视云-B股市,拨康视云-B股票价格,拨康视云-B股票交易,拨康视云-B股票购买,拨康视云-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拨康视云-B(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拨康视云-B(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}